Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

Back

ESC Premium Access

Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

Session: Obesity and pre-diabetes: where do we stand today on prevention and treatment?

Topic: Secondary Prevention

Speaker: Doctor S. Kahn (Seattle, US)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Steven Kahn

VA Puget Sound Health Care System and University of Washington, Seattle (United States of America)

2 presentations

0 follower

4 more presentations in this session

State-of-the-art lecture on obesity and pre-diabetes: where do we stand today on prevention and treatment?

Speaker: Professor E. Prescott (Copenhagen, DK)

Access

Slides

Video

Are metabolically healthy obese individuals really a benign cardiovascular group? An analysis of 162,590 participants with measures of arterial stiffness in UK BIOBANK

Speaker: Doctor R. Ananda (Melbourne, AU)

Association between normal range UACR and insulin resistance and prediabetes among US adults:

Speaker: Miss S. Wu (Beijing, CN)

Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.

Speaker: Doctor N. del-Cuerpo-Salinas (Sant Joan d'Alacant, ES)

Access the full session

Obesity and pre-diabetes: where do we stand today on prevention and treatment?

Speakers: Doctor S. Kahn, Professor E. Prescott, Doctor R. Ananda, Miss S. Wu, Doctor N. del-Cuerpo-Salinas

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources